Newsletters

[RadioMedix, Inc.] RadioMedix, Inc. announced that the US FDA has approved Ga 68 PSMA-11, a prostate-specific membrane antigen (PSMA)-targeted diagnostic radiopharmaceutical for positron emission tomography imaging in patients with prostate cancer.

[University of Houston] With $250,000 in Cancer Prevention and Research Institute of Texas (CPRIT) funding, Dr. Qin Feng, associate professor of biology and biochemistry, is working to stop the progression of prostate cancer. Her research goal is to provide a new treatment option for prostate cancer patients, especially those resistant to current therapies.

[Oncogene] Liquid chromatography-mass spectrometry identified LTBP1 as a direct interacting partner of methylcrotonyl-CoA carboxylase subunit 2 (MCCC2). Functional studies demonstrated that MCCC2 promotes prostate cancer cell migration, invasion in vitro, and bone metastasis in vivo.

[Cell Death & Disease] Researchers conducted pharmacological profiling, genetic dependency analysis, RNA sequencing, and functional validation across various in vitro and in vivo preclinical CRPC models.

[Cell Death & Disease] In prostate cancer, the development of resistance to androgen receptor-targeted therapies and chemotherapies is associated with the emergence of new phenotypic states with altered molecular features. Scientists identified ubiquitin-specific peptidase 2 (USP2) as a mediator of this phenomenon.

[CytoDyn, Inc.] CytoDyn, Inc. announced that the first patient has been dosed in a Phase IIa clinical study evaluating leronlimab in patients with Alzheimer’s disease, in collaboration with Weill Cornell Medicine.

[Circulation] Analyses supported Mastermind-like 1 (MAML1) as a candidate gene for congenital heart disease and identify MAML1 liquid-liquid phase separation as a critical biophysical determinant of Notch transcriptional output in endocardial cells.

[Gut] Scientists provided a comprehensive cellular map of human severe acute pancreatitis and uncover a pathogenic immune-endothelial circuit—orchestrated by the TNF-α/UL16-binding protein/NKG2D axis—that drives microcirculatory dysfunction.

[Circulation Research] Using a mouse model to specifically label lymphatic endothelial cells, researchers found that pulmonary lymphatic vessels proliferate and dilate in response to hypoxia. Vegfr3 inhibition using MAZ51 reduced hypoxia induced lymphangiogenesis and was associated with severe pulmonary hypertension.

[Molecular Psychiatry] In a rat preeclampsia model, offspring exhibited abnormal behaviors and reduced striatal vascular density, with disrupted blood-brain barrier and swollen astrocytes.

[UC Davis Health] A $4 million grant from the National Institutes of Health will help his UC Davis pediatric urologic surgeon Dr, Eric Kurzrock and collaborators test a bioengineered graft infused with ligands (molecules) to treat neuropathic bladders of children with spina bifida or spinal cord injuries.

[Nature Reviews Urology] Drawing on multi-ancestral comparative analyses, with emphasis on cohorts from sub-Saharan Africa, the authors speculate that germline and somatic variation converge in epigenetic machinery genes to drive tumor evolution.